

Docket No.: 15652-08500-US  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Peter Hansen et al.

Application No.: 10/572,706

Confirmation No.: 4535

Filed: January 8, 2007

Art Unit: 1625

For: 2-PYRIDONE DERIVATIVES AS  
NEUTROPHIL ELASTASE INHIBITORS  
AND THEIR USE

Examiner: Z. N. Davis

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action after the filing of a request for continued examination under § 1.114 pursuant to 37 CFR 1.97(b)(4) as far as is known to the undersigned. A copy of each document required under 37 CFR 1.98(a)(2) is enclosed.

The applications shown in the table below are possibly technically related to the present application:

U.S. Application Publication No. 2006/0270666
U.S. Application Publication No. 2006/0035938
U.S. Application Publication No. 2007/0010551
U.S. Application Publication No. 2007/0043036
U.S. Application Publication No. 2009/0131486

Applicants note that the references listed in the translation column of the attached Form PTO SB/08 are English-language counterparts from the same family of applications as the non-English foreign patent documents listed therein, but may not necessarily be their English-language equivalents.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such. Moreover, Applicants understand the Examiner will make an independent evaluation of the cited documents.

No fee is believed due. However, if a fee is due, the Director is hereby authorized to charge our Deposit Account No. 03-2775, under Order No. 15652-08500-US, from which the undersigned is authorized to draw.

Respectfully submitted,

Electronic signature: /Joseph A. Ciardi/  
Joseph A. Ciardi  
Registration No.: 64,760  
CONNOLLY BOVE LODGE & HUTZ LLP  
1007 North Orange Street  
P. O. Box 2207  
Wilmington, Delaware 19899-2207  
(302) 658-9141  
(302) 658-5614 (Fax)  
Agent for Applicant